Substituted pyridine compounds as CRAC modulators

摘要

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.;

主权项

1. A compound having the Formula (I): wherein, ring E is a 5-membered non aromatic heterocyclic ring X is —NR—; Y is —C(O)—; R is substituted or unsubstituted alkyl or haloalkyl; L is selected from —C(O)NR11—, —NR11C(O)— and —NR11CH2—; ring D is wherein A1 and A2 are CR3; R1, which may be same or different at each occurrence, is independently selected from halogen, cyano, nitro, hydroxyl, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, haloalkoxy and substituted or unsubstituted cycloalkyl; R2, which may be same or different at each occurrence, is independently selected from halogen, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, haloalkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkoxy, —NR6R7 and —NHC(O)R9; R3, which may be same or different at each occurrence, is independently selected from hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, haloalkyl, haloalkoxy, substituted or unsubstituted cycloalkyl, —NR6R7,—C(O)NR6R7 and —C(O)OR8; R6 and R7, which may be same or different at each occurrence, are independently selected from hydrogen, substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl; R8, which may be same or different at each occurrence, is independently hydrogen, substituted or unsubstituted alkyl; R9, which may be same or different at each occurrence, is independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl; R11 is hydrogen; ‘n’ is an integer ranging from 0 to 2, both inclusive; ‘p’ is an integer ranging from 0 to 3, both inclusive; ‘q’ is an integer ranging from 1 to 2, both inclusive; and where the substituents on alkyl, cycloalkyl, alkoxy, cycloalkoxy are independently selected from hydroxy, halogen, carboxyl, cyano, nitro, alkyl, haloalkyl, aryl, cycloalkyl, —C(O)ORx, —C(O)Rx, —C(O)NRxRy, —NRxC(O)NRyRz, —NRxRy, —NRxC(O)Ry, —S(O)2NRxRy, —ORx, —SRx, and —S(O)2Rx; wherein each occurrence of Rx, Ry and Rz are independently selected from hydrogen, halogen, alkyl, haloalkyl, and cycloalkyl; or a pharmaceutically acceptable salt thereof.